Aradigm Corporation (ARDM) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Aradigm Corporation (NASDAQ:ARDM) from a hold rating to a buy rating in a report released on Wednesday. The firm currently has $1.50 price objective on the stock.
According to Zacks, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung. “
Aradigm Corporation (NASDAQ ARDM) opened at 1.38 on Wednesday. The stock’s market cap is $19.91 million. The company has a 50-day moving average price of $1.33 and a 200 day moving average price of $1.45. Aradigm Corporation has a 1-year low of $0.78 and a 1-year high of $7.19.
Aradigm Corporation (NASDAQ:ARDM) last posted its earnings results on Thursday, August 10th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.37. Aradigm Corporation had a negative net margin of 196.65% and a negative return on equity of 665.03%. The business had revenue of $7.68 million during the quarter. Equities analysts expect that Aradigm Corporation will post ($0.74) earnings per share for the current fiscal year.
WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/aradigm-corporation-ardm-upgraded-at-zacks-investment-research/1538053.html.
Aradigm Corporation Company Profile
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.